Close Menu
Technology Mag

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Layoffs hit CNET as its parent company goes on a buying spree

    July 30, 2025

    How Do You Live a Happier Life? Notice What Was There All Along

    July 30, 2025

    Microsoft is getting ready for GPT-5 with a new Copilot smart mode

    July 30, 2025
    Facebook X (Twitter) Instagram
    Subscribe
    Technology Mag
    Facebook X (Twitter) Instagram YouTube
    • Home
    • News
    • Business
    • Games
    • Gear
    • Reviews
    • Science
    • Security
    • Trending
    • Press Release
    Technology Mag
    Home » The Case for MDMA’s Approval Is Riddled With Problems
    Science

    The Case for MDMA’s Approval Is Riddled With Problems

    News RoomBy News RoomJune 11, 20243 Mins Read
    Facebook Twitter Pinterest LinkedIn Reddit WhatsApp Email

    The results sounds promising, but Michael Ostacher, a professor of psychiatry and behavioral sciences at Stanford University who’s not involved with Lykos and wasn’t on the FDA panel, says there’s a big problem: “It’s unclear whether or not the participation in the study and anticipation of the effect is what makes people better, rather than the impact of the drug itself.”

    In medical research, a double-blinded placebo controlled trial—in which neither the participants nor the researchers know who gets a placebo or the experimental treatment—is considered the gold standard. But the effects of psychedelics are so well known that it’s easy for volunteers and therapists alike to guess whether they’d received it. Ostacher says the growing hype over psychedelics has created certain expectations for people enrolled in these studies.

    “My main concern is that people in the trial who did not receive the MDMA would experience a lot of disappointment about not getting the drug, and that would have a large influence on how they reported their symptoms,” he says. “In the same fashion, the people who did get the MDMA, which has been advertised by advocates as a life-changing treatment, would be inclined to feel positive about their experience.”

    This “unblinding” effect is a well known conundrum not just for Lykos, but for the entire field of psychedelics research also, and scientists are currently considering alternative ways of designing trials to account for this potential bias.

    Another issue surrounds the psychotherapy, or talk therapy, administered during the trial sessions. When participants took MDMA or placebo, two therapists were in the room to help them express and process their memories and emotions during eight-hour sessions. Lykos describes this therapy as a “personalized experience,” but FDA committee members had concerns with the variability in therapy approaches and how much of patient outcomes could be attributed to the drug itself versus the therapy.

    Natalie Gukasyan, an assistant professor of psychiatry at Columbia University who studies psychedelics, says “there’s a lot of wiggle room” in the Lykos manual on how the therapy session can be conducted. “If the treatment is medication-assisted psychotherapy, maybe a little bit more of a prescribed therapy is appropriate,” she says.

    The FDA does not regulate therapy, nor is it involved with credentialing of psychotherapists, which raises the question of how therapy would be standardized. Gukasyan wonders whether it’s appropriate for Lykos to be involved with training therapists because it could present a conflict of interest.

    While some of the participants who testified on Tuesday or submitted written comments to the committee described positive stories of their sessions and lasting benefits, others had negative experiences. In one particularly troubling report, former trial participant Meaghan Buisson testified that her therapists, a married couple, pinned her down on a bed while stroking and cuddling her. (New York Magazine reported on Buisson’s experiences two years ago, publishing a video of this incident.)

    Another volunteer, Sarah McNamee, wrote that during her MDMA session, her therapists told her she was “helping make history” and that she was “part of a movement.” According to McNamee, they encouraged her to give a positive report of the experience, saying her responses during and after the trial could jeopardize the drug’s legalization. When her mental health symptoms worsened, she was told she would feel better in six months.

    Share. Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Email
    Previous ArticleThe best thing about Jabra’s new earbuds is the case
    Next Article All three game console makers have now abandoned X integration

    Related Posts

    How Do You Live a Happier Life? Notice What Was There All Along

    July 30, 2025

    EPA Employees Still in the Dark as Agency Dismantles Scientific Research Office

    July 30, 2025

    This Star System Contains 5 Potentially Habitable Planets

    July 30, 2025

    The Hunt for a Fundamental Theory of Quantum Gravity

    July 29, 2025

    South Korea Plans to Build a Base on the Moon

    July 29, 2025

    The First Planned Migration of an Entire Country Is Underway

    July 29, 2025
    Our Picks

    How Do You Live a Happier Life? Notice What Was There All Along

    July 30, 2025

    Microsoft is getting ready for GPT-5 with a new Copilot smart mode

    July 30, 2025

    Google is using AI age checks to lock down user accounts

    July 30, 2025

    Meta’s AI Recruiting Campaign Finds a New Target

    July 30, 2025
    • Facebook
    • Twitter
    • Pinterest
    • Instagram
    • YouTube
    • Vimeo
    Don't Miss
    News

    You can hide an AirTag in Skechers’ new kids’ shoes

    By News RoomJuly 30, 2025

    If you’re a parent with kids in school or kids who are independently exploring their…

    Elon Musk’s Boring Company announces plan to tunnel under Nashville

    July 30, 2025

    Meta Is Going to Let Job Candidates Use AI During Coding Tests

    July 30, 2025

    Samsung Galaxy Z Flip 7 review: more of a good thing

    July 30, 2025
    Facebook X (Twitter) Instagram Pinterest
    • Privacy Policy
    • Terms of use
    • Advertise
    • Contact
    © 2025 Technology Mag. All Rights Reserved.

    Type above and press Enter to search. Press Esc to cancel.